PRODUCT LITERATURE

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and Nacetylcysteine

---

To date there are no head-to-head studies comparing different mucolytic/antioxidant agents. Considering the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstructive pulmonary disease (COPD), and the recent publication of Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD (RESTORE) study, we have performed a meta-analysis to compare the efficacy and safety of erdosteine 600mg/day, carbocysteine 1500mg/day, and N-acetylcysteine (NAC) 1200mg/day in COPD

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Erdosteine
COPD
Mucolytic
Carbocysteine

Specific Detail Info

Respiratory Research (2019) 20:104

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment